Holocene Advisors’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Holocene Advisors’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-679,238	Closed	-$80.5M	–	1079
2022 Q1	$80.5M	Buy	679,238 +385,395	+131%	+$48.1M	0.42%	78
2021 Q4	$40.5M	Sell	293,843 -5,171	-2%	-$658K	0.21%	132
2021 Q3	$41.5M	Buy	299,014 +286,750	+2,338%	+$35.8M	0.23%	136
2021 Q2	$1.19M	Buy	+12,264	New	+$995K	0.01%	644
2021 Q1	–	Sell	-12,393	Closed	-$1.06M	–	1015
2020 Q4	$1.06M	Buy	+12,393	New	+$1.05M	0.01%	533
2020 Q3	–	Sell	-80,865	Closed	-$5.91M	–	834
2020 Q2	$5.91M	Sell	80,865 -396,891	-83%	-$21.1M	0.05%	205
2020 Q1	$16.3M	Buy	+477,756	New	+$21.8M	0.17%	139

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors's BHVN Position: Q2 2022 in Review

Holocene Advisors sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 679,238 shares — an estimated $80.5M sold.

Holocene Advisors first reported a position in BHVN in Q1 2020 and held it in 7 quarters. The position peaked at $80.5M in Q1 2022. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

Holocene Advisors reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
Holocene Advisors sold 679,238 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $80.5M.
Holocene Advisors first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2020 and held it in 7 quarters.
Holocene Advisors's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $80.5M in Q1 2022.
329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Holocene Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.